- Home
- RMM vs FENC Comparison
RMM vs FENC Comparison
Compare RMM & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$12.09
Company Overview
Basic Information| Metric | RMM | FENC |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.7M | 230.8M |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | RMM | FENC |
|---|---|---|
| Price | $14.50 | $12.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 39.2K | ★ 166.7K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ N/A | $1,206.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.35 | $5.65 |
| 52 Week High | $15.00 | $13.25 |
Technical Indicators
Market Signals| Indicator | RMM | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 61.87 |
| Support Level | $13.92 | $7.40 |
| Resistance Level | $14.65 | N/A |
| Average True Range (ATR) | 0.20 | 0.75 |
| MACD | 0.02 | 0.22 |
| Stochastic Oscillator | 57.42 | 69.64 |
Price Performance
Historical Comparison RMM
FENC
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.